References
- Maini RN, Breedveld F, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
- Maini RN, St Clair EW, Breedveld FC, Furst DE, Kalden JR, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedfveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000;343:1594–62.
- Keane JK, Gershon S, Ftharm D, Wise RP, Mirabile-Levens E, Kasznica J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001;345:1098–104.
- Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infec-tion in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372–379.
- World Health Oraganization. WHO report. Global tuberculosis control - surveillance, planning, financing. http//www.who.int/tb/ publications/global-report/2004/en
- Ministry of Health, Labor, and Welfare, Japan. Report (in Japa-nese). hap://www.jata.or.jp/rit/rj/03toukei.jtml
- Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis (in Japanese). Ensho 1996;16:437–8.
- Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the inci-dence of Pneumocystis carinii pneumonitis. Cancer 1995;36:2004–9.
- Liam CK, Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992;1:379–85.
- Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Ftheumatol 1994;21:246–51.
- Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/der-matomyositis or systemic lupus erythematosus. J Ftheumatol 1996;23:1186–8.
- Ogawa J, Hariga MI, Nagasaka N, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis carinii pneumonia in patients with connective tissue diseases under-going high-dose corticosteroid therapy. Mod Ftheumatol; in press.
- Bergin CJ, Wirth RL, Berry GJ, Castellino RA. Pneumocystis carinii pneumonia: CT and HRCT observations. J Comput Assist Tomogr, 1990;14:756–9.
- Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1–3) p-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Chin Diagn Lab Immunol 1996;3: 197–9.
- Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315–24.
- Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122–27.
- Carmona L, Hernandez-Garcia C, Vadillp C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Ftheumatol 2003;30:1436–9.
- Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lance Infect Dis 2003;3:148–55.
- Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62(suppl II):ii37–42.